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Abstract
Background: Multifactor Dimensionality Reduction (MDR) has been widely applied
to detect gene-gene (GxG) interactions associated with complex diseases. Existing
MDR methods summarize disease risk by a dichotomous predisposing model
(high-risk/low-risk) from one optimal GxG interaction, which does not take the
accumulated effects from multiple GxG interactions into account.
Results: We propose an Aggregated-Multifactor Dimensionality Reduction (A-MDR)
method that exhaustively searches for and detects significant GxG interactions to
generate an epistasis enriched gene network. An aggregated epistasis enriched risk
score, which takes into account multiple GxG interactions simultaneously, replaces
the dichotomous predisposing risk variable and provides higher resolution in the
quantification of disease susceptibility. We evaluate this new A-MDR approach in a
broad range of simulations. Also, we present the results of an application of the
A-MDR method to a data set derived from Juvenile Idiopathic Arthritis patients
treated with methotrexate (MTX) that revealed several GxG interactions in the folate
pathway that were associated with treatment response. The epistasis enriched risk
score that pooled information from 82 significant GxG interactions distinguished
MTX responders from non-responders with 82% accuracy.
Conclusions: The proposed A-MDR is innovative in the MDR framework to
investigate aggregated effects among GxG interactions. New measures (pOR, pRR
and pChi) are proposed to detect multiple GxG interactions.
Keywords: A-MDR, Epistasis enriched risk score, Epistasis enriched gene network,
pRR, pOR, pChi

Background
Human diseases usually have complex inheritance patterns, and single nucleotide polymorphisms (SNPs) has been utilized to explain the variation in susceptibility to many
common complex diseases as well as the response to drug therapy. The advancement
of genotyping technology has made genotypic data readily accessible to investigators at
low cost. However, many challenges remain with regard to identifying genes that render people susceptible to non-Mendelian disorders and in understanding the associations and functional relationships among genes. More and more, researchers have been
advocating for advanced statistical analysis to quantify complex and interactive biological and genetic relationships [1,2].
© 2013 Dai et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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Multifactor Dimensionality Reduction (MDR) is a statistical paradigm for characterizing
and detecting nonlinear complex gene-to-gene interactions (epistasis) possibly associated
with susceptibility to disease [3]. When numerous genes are involved in a complex canonical pathway or network, traditional approaches for data analysis, such as a Chi-square test
or Fisher’s exact test, might not detect the associations between risk factors and outcomes
since these approaches assess only marginal main effects of the identified risk factors. Although one can employ logistic regression or other standard multivariate categorical data
analysis approaches to explore interactions among SNPs, there are an enormous number of
possible interactions in a model with both linear and nonlinear effects. Consequently, standard multivariate categorical data analysis approaches might detect very few interactions, and
even then the cost in terms of sample size might be immense. MDR addresses these difficulties by converting high-dimensional genotypic data into a single predictive variable. Genotypic combinations are used to define high risk and low risk strata for the one-dimensional
predisposing risk factor. MDR can reveal non-linear epistasis at a moderate sample size with
no requirements on the underlying distributions of genotypes or outcomes [4].
The most commonly used MDR approach is described in detail by Ritchie et al. [3]. To
distinguish this method from its various extensions, we will refer to it as the original MDR
method. Related statistical software has been developed by Hahn et al. [4], Bush et al. [5],
Winham and Motsinger-Reif [6], and Moore and colleagues (www.epistasis.org). In general,
the MDR process can also be combined with a filter preprocess step by first applying global
testing and filtration techniques to select the optimal number of SNPs for MDR analysis by
searching for a subset of genes likely to interact with other genes using the ReliefF filtering
process [7,8].
Details of the MDR [3] are briefly described here. MDR performs an exhaustive search of
all variables and variable combinations to identify univariate or multivariate disease risk
models. For each locus or multi-locus combination, attribute construction is performed to
make a single variable with two categories: high risk and low-risk. A genotype or combination of genotypes is assigned high risk status if the ratio of affected subjects to unaffected
subjects exceeds a pre-determined threshold, and low-risk otherwise. This step consolidates
the high-dimensional risk space into a one-dimensional predictive variable. Typically, a 5fold or 10- fold cross-validation procedure is employed, beginning with the random division
of the original data set into five or ten subsets of approximately equal sizes [9]. For 10-fold
cross-validation, a model is fit using nine of the ten subsets (collectively referred to as training data), and then the model is applied to classify observations in both the training data
and the tenth subset not used to fit the model (referred to as validation data). This entire
process is repeated ten times, with one of the ten subsets acting as the validation data [10].
The model’s training accuracy and testing accuracy are defined as the percentage of correct
classifications in the corresponding data sets. The optimal one-locus, two-locus, and threelocus MDR models with the highest testing accuracy are identified. A one-locus model estimates the main effect of each SNP, while multi-locus models investigate the interactions
among relevant SNPs. The cross validation consistency (CVC) is the number of times in a
10-fold cross validation that a particular multifactorial combination is identified as an optimal model for the training data. Finally, statistical significance of the optimal models is
assessed by 1000- or 10000-count permutation testing [11].
MDR has been applied to identify gene-gene interactions conferring susceptibility to
common diseases, including hypertension [12], bladder cancer [13], Type 2 diabetes [14],
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and rheumatoid arthritis [15,16]. Several extensions of the MDR method have been proposed. These methods entail the use of odds ratios [17], log-linear methods [18], generalized linear models [19], methods for data highly imbalanced with the disease outcome
[20], model-based methods [21], contingency table measures of classification accuracy
[22] and familial data [23,24].
In the present work, we propose an Aggregated-Multifactor Dimensionality Reduction
(A-MDR) method that exhaustively searches for statistically significant gene-gene (GxG)
interactions to generate a gene interaction network. In particular, an epistasis enriched
risk score replaces the traditional dichotomous predisposing risk factor in quantifying the
degree of susceptibility to a disease. We also introduce and compare new GxG interaction
measures (pOR, pRR and pChi). An adjustment for multiple comparisons is implemented
to limit false positive discoveries. In the current study we introduce the new approach,
evaluate its performance in a range of simulations, and apply it to a real dataset from Juvenile Idiopathic Arthritis patients treated with methotrexate (MTX).

Method
The A-MDR method proposed herein can be applied to detect interactions among alleles,
genotypes, and other categorical explanatory variables. Without loss of generality, we
present the A-MDR method for SNPs with three common states (0 - homozygous reference, 1 - heterozygous, 2 - homozygous variant). The steps of the A-MDR are outlined in
Figure 1.
Detect multiple GxG interactions using the pOR, pRR or pChi test

The starting point for the A-MDR method is the construction of a predisposing risk
factor. Suppose we want to investigate k–way GxG interactions among M SNPs. For one
particular k–way GxG interaction, there are 3k (SNP(1) = 0, 1, 2 × SNP(2) = 0, 1, 2 × ⋯ ×
SNP(k) = 0, 1, 2) different genotypic combinations. Denote these 3k genotypic combinations as Cij where j = 1, 2, ⋯, 3k stands for different genotypic combinations within one
 
M
k–way GxG interaction. We need another subscript i ¼ 1; 2; ⋯;
to cover all k–way
k
GxG interactions among M SNPs. Let Xij and Yij be the numbers of affected (Test) and unaffected (Control) subjects in the jth genotypic combination of the ith k–way GxG inter!
!
3k
3k
3k
X
X
X
action. Let pi0 ¼
Xij =
Xij þ
Yij ∈ð0; 1Þ be the threshold for disease
j¼1

j¼1

j¼1

risk above which a person is deemed highly susceptible using a Naïve Bayes classifier [25]. Genotypic combinations are then classified into high-risk predisposing
risk groups and low-risk predisposing risk groups, n11,n12,n21,n22, in Table 1
where I{·} denotes an indicator function.
We propose to perform one of the following measures to assess the ith k–way GxG interaction (the subscript i is omitted for n’s and e’s):
(a) the predisposing odds ratio (pOR),
pORi ¼

n11 n22 =ðn12 n21 Þ
;
F01 ðF ðn11 n22 =ðn12 n21 ÞÞÞ

ð1Þ
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Test all k − way GxG interactions among M SNPs.
Perform pOR, pRR or pChi test to assess the significance of each k − way
GxG interaction using 95% CI and p-value. See Formula 1-3.

Non-significant GxG interactions will be removed from further analysis. Pvalues may be adjusted by multiplicity algorithms (i.e. FDR).

th

th

For the n subject, we assign 1 if the n subject carries a high
predisposing risk genotypic combination and assign 0 if the n
carries a low risk genotypic combination. See Formula 4.

th

subject

The risk score will be aggregated (added) together over all k-way GxG
interactions for each subject. Higher score indicates that a subject carries
more high risk genotypic combinations. See Formula 4.
The AUC under ROC curve provides an overall evaluation of the epistasis
enriched risk score’s ability to predict disease risk. The final epistasis
enriched risk score will be generated based on GxG interactions passing the
p-value (or FDR) hurdle α̂ that maximizes the AUC of ROC curves. See
Formula 5.
Finally, the epistasis enriched risk score, R (k , n) , is treated as a diagnostic
test for the disease. See Figure 2B.

The significant GxG interactions used to define the epistasis enriched risk
score are collectively referred to as an epistasis enriched network. See
Figure 2A.
Figure 1 Flow chart of Aggregated-Multifactor Dimensionality Reduction (A-MDR).

(b) the predisposing relative risk (pRR),

pRRi ¼

n11 =ðn11 þn12 Þ
n21 =ðn21 þn22 Þ

F01 F



;

ð2Þ

n11 =ðn11 þn12 Þ
n21 =ðn21 þn22 Þ

and
(c) the predisposing chi-square (pChi) test statistic,
Table 1 2x2 Predisposing risk table (Subscript i is omitted for n’s.)
Case
High Predisposing Risk

n21
Total

n+1





Xij
> pi0
X
þ Yij
ij
j¼1


3k
X
Xij
¼
Xij I
≤pi0
Xij þ Yij
j¼1

n11 ¼

Low Predisposing Risk

Control
3k
X

Xij I

n+2

Total




Xij
> pi0
X
þ Yij
ij
j¼1


3k
X
Xij
¼
Yij I
≤pi0
Xij þ Yij
j¼1

n12 ¼

n22

3k
X

Yij I

n1+

n2+

N
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2 X
2
X
ðnst  est Þ2
est
s¼1 t¼1

F01 F

2 X
2
X
ðnst  est Þ2
est
s¼1 t¼1

!;

ð3Þ

where est ¼ nsþNnþt is the expected number of subjects in predisposing risk stratum s
(1 = high predisposing risk, 2 = low predisposing risk) and disease stratum t (1 = Case,
2 = Control) under a null hypothesis of no association between the predisposing risk factor and the disease. Details of F and F0, along with permutation tests and 95% confidence
intervals for pOR, pRR and pChi are in Appendix I.
Aggregate high risk from significant GxG interactions into risk scores

Assume a study investigates a total of N subjects. For the nth (n = 1, 2, ⋯, N) subject,
an aggregated k–way epistasis enriched risk score, R(k,n), is defined by
 
8
M
>
>
>
"
#
>
k
<
3k
X
X


^g
ð4Þ
I fPvaluei < α
I n∈Cij I Xij = Xij þ Yij > pi0
Rðk; nÞ ¼
>
>
i¼1
j¼1
>
>
:

^ ¼ arg max fAUC jαg
α

ð5Þ

0≤α≤0:05

^ g, to remove the ith nonIn equation (4), we use the indicator variable, I fPvaluei < α
significant GxG interaction from further calculation of risk scores. For the remaining
significant GxG interactions, the indicator function, I{n ∈ Cij}I{Xij/(Xij + Yij) > pi0},
assigns 1 if the nth subject carries a high predisposing risk genotypic combination and 0
if the nth subject carries a low predisposing risk genotypic combination. More specifically, I{Xij/(Xij + Yij) > pi0} indicates whether the jth genotypic combination has high predisposing risk and I{n ∈ Cij} checks whether the nth subject carries the jth genotypic
combination. Each subject’s risk scores are then summed over all 3kgenotypic combinations and all k–way GxG interactions to obtain an aggregated k–way epistasis enriched
risk score, R(k,n), for the nth subject.
Finally, the epistasis enriched risk score, R(k,n), is treated as a diagnostic test for the
disease. One can consider adding up the predisposing scores with p < 0.05 from these
interactions. Our experience has been that, in many cases, α=0.05 is an arbitrary cutoff
for p-values and some GxG interactions with p-value < 0.05 might have low predictive
ability. Therefore, a receiver operating characteristic (ROC) curve is constructed, and
the area under the ROC curve (AUC) provides an overall evaluation of the epistasis
enriched risk score’s ability to predict disease susceptibility. Instead of using an arbi^ that maximizes the AUC of ROC curves.
trary cutoff α=0.05, we propose to select α
^ ≤0:05 may help focusing on a modest number
^ ¼ arg max fAUC jαg for α
Choosing α
0≤α≤0:05

of summands that are most conducive to correct classification (arising from the strongest GxG interactions), rather than diluting the epistasis enriched risk score R(k,n) by a
large number of summands that are not as conducive to correct classification (arising
from comparatively weaker GxG interactions).
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Construct multiple GxG interactions into an epistasis enriched network

The significant GxG interactions used to define the epistasis enriched risk score are
collectively referred to as an epistasis enriched network (Figure 2A). Genes involved in
one or more significant interactions appear as nodes in a radial graph. Pairs of genes sharing significant interactions are connected by lines. Each line is labeled with the corresponding pOR, and the line thickness may be chosen to accentuate the strongest pORs.
In summary, the A-MDR method has not only replaced the dichotomous predisposing risk factor with a continuous predictive variable, R(k,n), but has done so by integrating numerous significant GxG interactions into an epistasis enriched network that may
more adequately explain the susceptibility to complex diseases. Epistasis enriched risk
scores may also be accumulated over GxG interactions from multiple dimensions. For
instance, we can accumulate both two-way and three-way GxG interactions. Or further
consider accumulating one way main effects and up to k–way GxG interactions. The
feasibility of these extensions needs to be assessed by future studies.

Empirical assessment
Extensive Monte Carlo simulations were performed to assess the performance of
pOR, pRR and pChi and compare them to the original MDR in unrelated case–
control studies. To avoid subjective selections of models in favor of our methods,
we report the power and type I error simulation similar to the models previously
assessed by [26]. In each model, we simulated five SNPs with common homozygote
(AA), heterozygote (Aa) and rare homozygote (aa). The minor allele frequencies
(MAF) in each model were set to be 0.5 and 0.25 respectively and the genotypes
were generated according to proportional expectations under Hardy-Weinberg
equilibrium and linkage equilibrium. Equal numbers of affected and unaffected subjects were generated based on penetrance functions given in Table 2. Let D=1 indicate the onset of disease and l1,l2.....,l5 stand for five loci, Pl1×l2 and Pl4×l5 be
penetrance functions from loci 1x2 and loci 4x5 respectively as listed in Table 2.
Our simulations comprised three major scenarios:

Figure 2 Panel A: gene-gene interaction network of 7 SNPs associated with susceptibility to active
arthritis. Significant GxG interactions (FDR<0.05) are connected by line, and the strength of interaction is
labeled with pOR. A larger pOR indicates a stronger interaction (thicker line) while a smaller pOR value
indicates a relatively milder interaction (thinner lines). Panel B: ROC curve for risk scores derived from 82
significant two-locus interactions pooled from 34 SNPs. The risk score is significantly higher in patients with
a poor response to MTX (active arthritis; inset).
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Table 2 Simulated gene-gene interaction models with varying penetrance functions and
minor allele frequencies
Model 1

Model 2

BB

Bb

bb

BB

AA

0

0.1

0

AA

Bb

bb

0

0

0.1

Aa

0.1

0

0.1

aa

0

0.1

0

Aa

0

0.05

0

aa

0.1

0

0

(A) MAF=0.5

(B) MAF=0.5

Model 3

Model 4

BB

Bb

bb

BB

Bb

bb

AA

0.08

0.07

0.05

AA

0.09

0.05

0.02

Aa

0.1

0

0.1

Aa

0.08

0.09

0.01

aa

0.03

0.1

0.04

aa

0.03

0.01

0.03

(C) MAF=0.25

(D) MAF=0.25

A) Existence of only one two-way interaction in loci 1x2 associated with disease
susceptibility while the remaining loci were unrelated to the outcome variable, i.e.
P(D = 1|l1, l2) = pl1 × l2.
B) Genetic heterogeneity models where a proportion of affected subjects are linked with
interactions between loci 1 and 2 and the rest of affected subjects are linked with
interactions between loci 4 and 5, i.e.
PðD ¼ 1; C jl1; l2; l4; l5Þ ¼ PðD ¼ 1jl1; l2; l4; l5; C ¼ 0Þ  P ðC ¼ 0Þ
þPðD ¼ 1jl1; l2; l4; l5; C ¼ 1Þ  PðC ¼ 1Þ ¼ PðD ¼ 1jl1; l2Þ  PðC ¼ 0Þ
þP ðD ¼ 1jl4; l5Þ  P ðC ¼ 1Þ ¼ γ 1 pl1l2 þ γ 2 pl4l5
where γ1≥0,γ2≥0 and γ1+γ2=1. The latent binary variable C labels the source of genetic variation where C=0 indicates that disease is related to loci 1x2 with P(C=0)=γ1 and C=1 indicates that disease is related to loci 4x5 with P(C=1)=γ2. In this study, we consider balanced
genetic heterogeneity models with γ1=γ2=0.5 and unbalanced genetic heterogeneity models
with γ1=0.7 and γ2=0.3.
C) Additive models with two pairs of loci jointly contributing to disease susceptibility. Let
Dl1×l2=1 denote the onset of disease due to the penetrance Pl1×l2 from loci 1*2 and Dl4×l5=1
due to the penetrance Pl4×l5 from loci 4*5. The susceptibility function is given by
P ðD ¼ 1jl1; l2; l4; l5 Þ ¼ PððDl1xl2 ¼ 1Þ [ ðDl4xl5 ¼ 1Þjl1; l2; l4; l5Þ ¼ PðDl1xl2 ¼ 1jl1; l2; l4; l5Þ
þPðDl4xl5 ¼ 1jl1; l2; l4; l5Þ  PððDl1xl2 ¼ 1Þ \ ðDl4xl5 ¼ 1Þjl1; l2; l4; l5Þ
¼ PðDl1xl2 ¼ 1jl1; l2Þ þ PðDl4xl5 ¼ 1jl4; l5Þ  PðDl1xl2 ¼ 1jl1; l2Þ
PðDl4xl5 ¼ 1jl4; l5Þ ¼ pl1l2 þ pl4l5  pl1l2 pl4l5

To assess the power of the A-MDR method, we randomly generated 100 sets of data in
the above described scenarios and performed the MDR and A-MDR tests for each random
sample. The power is the percentage of rejection of null hypothesis for the loci with a GxG
interaction. Type I error is the percentage of rejection of null hypothesis when the simulated
loci have no GxG interaction.
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As shown in Table 3, the Type I errors of all tests were under the nominal rate
of 5%. When only loci 1 and 2 had an interaction (Table 3A), all five measures
had strong power to detect GxG interactions in most models except that the
power of MDR dropped to 0.46 in model 3 with n=300, which could be enhanced
by increasing sample size. We next simulated genetic heterogeneity (Table 3B) with
0.5/0.5, 0.7/0.3 proportions of subjects affected by a mixture model of epistasis
from loci 1x2 and loci 4*5. We noticed that MDR lost power to detect interactions
with weaker effects. The power was not recovered with increased sample sizes. We
last examined the additive models (Table 3C) where susceptibility increases jointly
through loci 1x2 and loci 4x5. MDR has low power to detect both pairs of GxG
interactions. All this evidence suggests that the proposed A-MDR might be a better
choice for detecting complex GxG interactions, especially when multiple GxG
interactions are cumulatively contributing to a phenotype.

Table 3 Power and type I error assessment
A) Only Locus1*2
has an interaction

Model 1 (n=300)

Model 2 (n=300)

Model 3 (n=300)

Model 4 (n=300)

Power

Type I

Power

Type I

Power

Type I

Power

Type I

A-MDR pOR

1

0.01

1

0.01

0.75

0.01

1

0.03

A-MDR pRR

1

0

1

0.01

0.71

0.01

1

0.03

A-MDR pChi

1

0.01

1

0

0.86

0.03

1

0

MDR

1

0

1

0

0.46

0.02

1

0

A) Only Locus1*2
has an interaction

Model 1 (n=400)

Model 2 (n=400)

Model 3 (n=400)

Model 4 (n=400)

Power

Type I

Power

Type I

Power

Type I

Power

Type I

A-MDR pOR

1

0

1

0

0.86

0

1

0.02

A-MDR pRR

1

0

1

0

0.87

0

1

0.03

A-MDR pChi

1

0.02

1

0.01

0.95

0.01

1

0.02

MDR
B) Genetic heterogeneity
γ1=γ2=0.5

1

0

1

0

0.68

0.01

1

0

Model
1

Model
2

Model
1

Model
2

Model
3

Model
4

Model
3

Model
4

n=400 Power

n=800 Power

n=400 Power

n=800 Power

A-MDR pOR

0.98

1

1

1

0.37

0.91

0.7

A-MDR pRR

0.99

1

1

1

0.35

0.78

0.68

1
1

A-MDR pChi

0.99

1

1

1

0.31

0.99

0.72

1

MDR

0.12

0.75

0.08

0.78

0

0.69

0

0.92

B) Genetic heterogeneity Model 1 Model 2 Model 1 Model 2 Model 3 Model 4 Model 3 Model 4
γ1=0.7,γ2=0.3
n=400 Power
n=800 Power
n=400 Power
n=800 Power
A-MDR pOR

1

0.35

1

0.98

0.55

A-MDR pRR

1

0.25

1

0.97

A-MDR pChi

1

0.5

1

0.99

MDR

1

0

0.99

0

C) Additive Models

0.35

0.92

0.78

0.55

0.3

0.91

0.74

0.6

0.49

0.96

0.86

0.14

0.21

0.14

0.38

Model 1 Model 2 Model 1 Model 2 Model 3 Model 4 Model 3 Model 4
n=400 Power

n=800 Power

A-MDR pOR

n=400 Power
1

0.72

1

1

0.6

0.16

0.93

0.61

A-MDR pRR

1

0.69

1

0.98

0.61

0.14

0.91

0.55

1

0.79

1

1

0.71

0.29

0.98

0.76

0.91

0.02

0.99

0.01

0.26

0.14

0.43

0.12

A-MDR pChi
MDR

n=800 Power

(Within each cell, loci 1x2 is listed in the first column and loci 4x5 is in the second column).
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Application to genotyping data
Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases of childhood, affecting an estimated 300,000 children in the U.S. alone, and is an important
cause of morbidity and disability in children. Although methotrexate (MTX) is the
most commonly used second-line anti-inflammatory agent used to treat JIA worldwide,
this antifolate prodrug has shown considerable inter-individual variability in clinical response and adverse reactions. Thus far, variables investigated as potential useful predictors of response and toxicity in patients taking MTX, which is used alone and as an
“anchor drug” for many rheumatic conditions, have not been clearly associated with
outcomes. The effect of individual genetic SNP variation within the folate pathway
upon MTX response has been investigated in several studies in adult rheumatoid arthritis (RA) and a few studies in JIA with conflicting results. To elucidate the genetic
architecture impacting the efficacy of MTX, 34 SNPs from 19 folate pathway genes
were measured in 104 subjects. Response-defined as the absence of active arthritis
(swelling not due to bony enlargement or, if no swelling was present, limitation of motion accompanied by either pain on motion or tenderness, not due to trauma or
explained by prior joint damage [27]-was determined for these subjects. Information
pertaining to the 34 SNPs is listed in Table 4; demographic and clinical characteristics
of the subjects were described by Becker and colleagues [15]. After being on a stable
dose and route of MTX for at least 3 months, 56.7% of the patients (59 out of 104) still
had at least 1 active (i.e., swollen or tender) joint. The presence of active arthritis was
the outcome variable, and represented an incomplete response to MTX. By definition,
the absence of active arthritis-no joint involvement-was considered a positive response
to MTX treatment.
Standard logistic regression analysis did not identify significant main effects from SNPs
or GxG interactions. This could primarily due to the complex and non-linear interactions
among SNPs. For the rest article, the A-MDR and original MDR methods were applied to
the MTX data to search for genetic predictors of response to MTX. Redundant SNPs and
SNPs with no prediction of the phenotype were removed by the ReliefF algorithm [7]. A
complete set of 34 SNPs and 7 filtered SNPs were analyzed respectively.
The original MDR analysis method was applied to obtain the one-locus, two-locus,
and three-locus models with the highest validation accuracy in the original MDR. Twolocus interactions between genes ATIC and MTHFD2 were significant in testing accuracy but not in CVC. The prediction accuracy from the optimal MDR model was 75%.
We then utilized pOR, pRR, and pChi to identify and characterize GxG interactions
in the A-MDR analyses. Numerous two-locus GxG interactions were significantly associated with efficacy of MTX based on pOR, pRR, and pChi. We found that pChi flagged
the most GxG interactions as significantly associated with efficacy of MTX. After we
used the ReliefF algorithm to narrow down the list of candidate SNPs to 7, 15 pairs
GxG interactions were flagged as significant after FDR correction. Table 5 lists pOR,
pRR, and pChi along with 95% confidence intervals, unadjusted p-values, and FDRadjusted p-values for two-locus GxG interactions among 7 filtered SNPs. For the most
part, the three measures of GxG interactions (pOR, pRR, and pChi) yielded unadjusted
p-values that were in qualitative agreement. The epistasis-enriched network based on
the 15 significant two-locus GxG interactions from seven SNPs in five genes appears in
Figure 2A.
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Table 4 List of 34 SNPs from 18 candidate genes in the folate pathway
Gene

RS#

Gene

RS#

ABCG2

rs7699188

GGH

rs3758149

−15846A>C

ADORA2a

rs11545078

rs35252139

ITPA

rs2295553

rs35229708

MTHFD1

rs2236225

rs55930652

MTHFD2

5nt ins/16nt del

rs2298383

rs56168672

rs3761422
rs2267076

rs12196
MTHFR

rs2236624
ATIC

rs1801133
rs1801131

rs2372536

rs2274976

rs12995526

MTR

rs1805087

rs4673990

MTRR

rs1801394

BHMT

rs3733890

SHMT-1

rs1979277

DHFR

19 bp deletion

SLC25A32

rs17803441

rs7387

SLCO1B1

Rs4149056

GART

rs8971

SLC19A1

rs1051266

TSER

rs34743033

TYMS

rs11280056

Another goal of our A-MDR analysis was to integrate numerous significant GxG
interactions into a continuous epistasis enriched risk score for the prediction of which
patients would have active arthritis despite MTX treatment. A higher epistasis enriched
risk score would indicate that a patient carried more high-risk genotypic combinations
in loci with significant GxG interactions, and vice versa. To compare prediction accuracies based on the number of candidate SNPs as well as the presence or absence of adjustment for multiple comparisons, we generated epistasis enriched risk scores from 82
significant GxG interactions from 34 SNPs (Figure 2B).
Subjects with persistent active arthritis had significantly higher mean and median
epistasis enriched risk scores compared to subjects without active arthritis (p < 0.0001).
When 82 GxG interactions from 34 SNPs with unadjusted p-values < 0.0167 were used
to generate epistasis enriched risk scores (Figure 2B boxplot inset), these scores ranged
from 0 to 44. A higher risk score suggests that a subject is less likely to respond favorably to MTX treatment. The ROC curve assessing the overall ability of the epistasis
enriched risk score to distinguish between subjects with active joints and subjects without active joints had 85% area under the curve (p < 0.0001). (The 0.0167 cutoff for unadjusted p-values was chosen to maximize this area.) We correctly classify 82% of the
subjects if we predict that those with epistasis enriched risk scores above 11.5 have
active joints and that those with epistasis enriched risk scores below 11.5 do not have
persistent joint involvement.
Examination of the five genes in the 15-interaction model presented in Figure 2A
reveals a testable hypothesis for future studies. All genes fall within a pathway leading
to purine biosynthesis and adenosine formation: SLC25A32 transports folates from the
cytoplasm to mitochondria; MTHFD2 is a component of the mitochondrial folate pathway that produces one-carbon donors in the form of formate (10-formyl-tetrahydrofolate) exclusively to support de novo purine biosynthesis; and ITPA, ATIC, and GART
are involved in purine biosynthesis. Thus, all genes map to a core pathway associated
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Table 5 Two-locus GxG interactions among 7 SNPs assessed by A-MDR
Two-locus
GxG Interactions

pOR

p-value FDR

pRR

p-value FDR

pChi

p-value FDR

ATIC rs4673990+
MTHFD2 rs12196

3.9
0.001*
(1.6–13.1)

0.013* 1.9
0.001*
(1.2-4.1)

0.027* 6.1
<.001*
(1.8-21.1)

0.002*

ATIC rs4673990 +
MTHFD2
5nt ins/16nt del

3.7
0.001*
(1.5-12.8)

0.013* 1.8
0.003*
(1.1-3.6)

0.032* 6.0
<.001*
(1.6-22.0)

0.002*

MTHFD2 rs12196 +
GART rs8971

2.8
(1.1-8.8)

0.013*

0.069

1.6
0.016*
(0.9-3.4)

0.050

5.5
0.001*
(1.3-20.7)

0.009*

MTHFD2 5nt ins/16nt
del + GART rs8971

2.6
(1.0-7.9)

0.017*

0.069

1.5
0.017*
(0.9-2.7)

0.050

5.0
0.002*
(1.1-20.6)

0.011*

ATIC rs4673990 +
GART rs8971

2.5
(1.1-8.8)

0.027*

0.071

1.4
0.038*
(0.9-2.4)

0.088

4.7
0.009*
(1.1-19.2)

0.019*

ATIC rs2372536 +
MTHFD2
5nt ins/16nt del

2.5
(1.0-8.3)

0.017*

0.069

1.6
0.006*
(1.0-3.6)

0.041* 5.0
0.011*
(1.1-17.6)

0.020*

ATIC rs2372536 +
MTHFD2
rs12196

2.4
(0.9-8.0)

0.021*

0.069

1.4
0.033*
(1.0-3.0)

0.088

5.6
0.008*
(1.2-18.3)

0.019*

ATIC rs2372536 +
GART rs8971

2.2
(0.8-6.5)

0.032*

0.074

1.5
0.015*
(0.9-2.8)

0.050

4.5
0.012*
(0.8-28.2)

0.020*

SLC25A32 rs17803441 +
ITPA rs2295553

2.4
(0.8-7.5)

0.023*

0.069

1.6
0.013*
(1.0-2.8)

0.050

4.2
0.005*
(0.8-17.9)

0.019*

ATIC rs4673990 +
SLC25A32
rs17803441

2.3
(0.8-8.2)

0.039*

0.081

1.4
0.061
(0.8-2.2)

0.106

4.9
0.009*
(0.9-30.9)

0.019*

MTHFD2 rs12196 + ITPA
rs2295553

2.1
(0.9-7.1)

0.047*

0.090

1.4
0.065
(0.8-2.1)

0.106

4.2
0.025*
(1.0-16.0)

0.034*

ATIC rs4673990 + ITPA
rs2295553

2.3
(0.7-7.1)

0.074

0.101

1.4
0.076
(0.7-2.2)

0.106

3.7
0.045*
(0.9-13.2)

0.059

MTHFD2 rs12196 +
SLC25A32
rs17803441

2.2
(0.7-6.9)

0.060

0.097

1.4
0.067
(0.8-2.3)

0.106

5.2
0.012*
(0.9-27.2)

0.020*

ATIC rs2372536 +
SLC25A32
rs17803441

2.2
(0.7-6.1)

0.056

0.097

1.3
0.062
(0.9-2.7)

0.106

6.6
0.008*
(0.9-37.9)

0.019*

MTHFD2 5nt ins/16nt
del + MTHFD2 rs12196

2.0
(0.9-7.0)

0.074

0.101

1.3
0.088
(0.9-2.2)

0.115

5.2
0.008*
(0.8-33.1)

0.019*

MTHFD2 5nt ins/16nt
2.0
del +LC25A32 rs17803441 (0.6-5.9)

0.077

0.101

1.3
0.073
(0.9-3.3)

0.106

4.2
0.015*
(0.7-25.5)

0.023*

MTHFD2 5nt ins/16nt
del + ITPA rs2295553

1.9
(0.8-6.4)

0.114

0.139

1.3
0.129
(0.9-2.6)

0.160

3.9
0.076
(0.8-14.6)

0.094

ATIC rs2372536 + ITPA
rs2295553

1.9
(0.8-6.9)

0.119

0.139

1.3
0.182
(0.9-2.2)

0.201

3.9
0.091
(0.8-13.3)

0.101

GART rs8971 + ITPA
rs2295553

1.9
(0.8-8.9)

0.186

0.195

1.3
0.217
(0.9-3.6)

0.228

4.7
0.124
(0.8-16.1)

0.130

ATIC rs2372536 + ATIC
rs4673990

1.8
(0.7-5.3)

0.131

0.145

1.2
0.161
(0.8-2.0)

0.188

4.0
0.089
(0.7-23.3)

0.101

GART rs8971 + SLC25A32
rs17803441

1.7
(0.4-9.9)

0.227

0.227

1.2
0.296
(0.7-5.7)

0.296

3.5
0.156
(0.4-19.1)

0.156

(Three measures of GxG interactions [pOR, pRR, and pChi] along with 95% confidence intervals [CI] were obtained for
each two-locus GxG interaction. The p-value columns list unadjusted p-values, while the FDR columns list p-values after
adjustment for multiple comparisons. Significant GxG interactions, as judged by p-value or FDR less than 0.05, are
labeled with asterisks. The first GxG interaction in the table was the optimal two-locus GxG interactions identified by the
original MDR method with significant testing accuracy but insignificant CVC).
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with adenosine accumulation, which is considered to be a mechanism of action of
MTX that contributes to response in JIA and Rheumatoid Arthritis.

Discussion
In this work, we have proposed an Aggregated Multifactor Dimensionality Reduction
(A-MDR) model to elucidate complex and non-linear genetic associations contributing to
disease risk and variability in response to treatment. The proposed method is innovative in
three important ways: 1) a continuous GxG enriched risk score is generated to replace the
dichotomous risk factor in prediction of susceptibility to disorders; 2) new measures of
gene-gene interaction using pOR, pRR, and pChi along with p-values and confidence intervals are proposed to detect and characterize multiple gene-gene interactions; and, 3) a radial
network is generated to depict patterns of epistasis. This approach allows for prediction on
not just a single interactive model, which is important given the growing appreciation in
human genetics for the accumulative impact of a large number of variants with low effect
size [28]. By pooling moderate and inter-related genetic contributors together, the A-MDR
model becomes robust and predictive of complex traits. In addition to GxG interactions,
the A-MDR can also be applied to model gene-environment interactions where environmental risk factors such as smoking, alcohol consumption, exercise, and diet can be incorporated into multi-factorial models.
The original MDR model selects an optimal multi-factorial (SNP) combination for each
two-way, three-way or higher order interaction. When multiple genes function together
in a pathway, the original MDR is prone to overlook genes with weaker signals and lose
power for selecting one optimal GxG interaction in cross-validation. For the MTX data,
the optimal two-locus interaction detected by the original MDR among 7 candidate SNPs
was ATIC (rs4673990) + MTHFD2 (rs12196) with testing accuracy of 0.73 (p=0.0005).
However, there exist other pairs of interactions with comparable accuracy. As a result,
CVC, which measures the percentage of times that an optimal GxG interaction is selected
when splitting the training and validation sets randomly, was not significant (CVC=8/10,
p=0.2700). Our A-MDR analysis in Table 5 identified 15 pairs of two-locus interactions.
When multiple GxG interactions with bio-equivalent effects are involved in epistasis, the
original MDR will select an optimal model, by chance and lose some of the real pathwaybased signals. The recent extended MDR methods, including OR-MDR [17], LM-MDR
[18] and G-MDR [19], adopt the same strategy of selecting one optimal GxG interaction
as does the original MDR, which means they have the same limitations.
A continuous GxG enriched risk score is another major distinction between A-MDR and
all the majority of existing MDR models, in which a binary risk factor is utilized to predict
the outcome variable. For M-way interactions, the existing MDR models classify ~3M genotypic combinations as either high-risk or low-risk. A-MDR evolves from the traditional
MDR outputs to the predisposing risk scores and epistasis based network as shown in
Figure 2.
Another important result of the simulation experiments is the potential of A-MDR to
detect models that include genetic heterogeneity. Previous work with the original MDR
has shown that heterogeneity is disastrous when using MDR to detect interactions [26]
[29]. Because of the use of the continuous enrichment score, A-MDR is less impacted by
heterogeneity in the enclosed simulations. Further evaluation of this initial result with
expanded simulations and real data applications will be an important next step.
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We explore a radial network (Figure 2A) to depict patterns of epistasis. From the systems biology perspective, genetic variants might jointly impact the disease susceptibility
and response to treatment. The gene-gene interaction network reveals intriguing information when interpreted in the context of what we know about the folate pathway and the
effect that MTX has upon the disruption of this pathway as it relates to arthritis. ATIC
and MTHFD2 were the two genes with the strongest interaction, and it is of interest to
note that the genes included in the model (Figure 2A) include a transporter involved in
folate uptake into mitochondria, SLC25A32, and the bifunctional methylenetetrahydrofolate dehydrogenase-cyclohydrolase MTHFD2, a key constituent of the mitochondrial folate pathway. The mitochondrial folate pathway is responsible for the generation of
formate (in the form of 10-formylTHF) specifically to support purine biosynthesis, represented by ATIC, GART, and ITPA. The anti-inflammatory effect of low-dose MTX used
to treat JIA and RA is thought to be due the anti-inflammatory effects of adenosine,
formed as a consequence of the inhibitory effects of MTX on amino-imidazole carboxamide ribonucleotide (AICAR) transformylase (gene name, ATIC), which promotes the accumulation of AICAR ribotide, inhibiting adenosine deaminase and leading to a build up
of adenosine, a potent anti-inflammatory agent [30]. A disruption of this process may result in a decreased anti-inflammatory effect of the drug. Therefore, the combined effect of
SNPs in ATIC and MTHFD2 may indeed yield a more clinically apparent result by altering
the anti-inflammatory effects of methotrexate. There is a potential to apply the proposed
method to GWAS study by dissecting SNPs into pathways in order to detect GxG interactions in GWAS pathways. The major computational challenges from the proposed
A-MDR and other approach in MDR framework are in the generation of p-values for
MDR. MDR permutation computing time is largely dependent on the dimension of data
sets. In other words, the computing time increases as the number of SNPs and/or the
number of subjects increases. Several works have been devoted to improve the efficiency
and shorten the computing time in MDR analysis in high-throughput data [5,31,32]. We
will defer interested readers to the corresponding citations for computing issues in highthroughput MDR analysis. These computational limitations make our strategy appropriate
in large scale candidate gene studies, but may be limited in application to genome-wide
association studies until further improvements in computing speed are realized or very
large-scale computing resources are available.
In summary, bioinformatics challenges remain in detecting and modeling epistasis in
complex biological traits. We have developed a new A-MDR framework to interpret complex genetic variation and have proposed predicting an outcome using a continuous risk
factor. Several other extensions and modifications of the original MDR have been proposed in the literature. Incorporation of valuable features from other MDR extension
models into the A-MDR framework is worth further investigation. Prospective studies
and validation in independent samples are needed to assess reliability of the A-MDR
model’s predictive ability. Tools for statistical inference, including asymptotic distributions
of the proposed test statistics, need to be developed to save computing time and improve
reliability.

Appendix
Appendix I. Justification, 95% confidence intervals and permutation tests of pOR, pRR
and pChi.
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Since the predisposing risk factor (Table 1) is conditioned on the naïve Bayes classifier, standard inference procedures based on normal or chi-square asymptotic distributions with 1 degree of freedom do not apply to the numerators in (1)-(3), which are the
unadjusted odds ratio (OR), relative risk (RR) and Chi-square statistics (Chi). As a
result, 95% confidence intervals of OR and RR are often greater than 1 under H0. To
address this issue, we propose pOR, pRR and pChi by taking the null distribution of
unadjusted statistics into account. Let x=pOR,pRR, or pChi, F(x) be the cumulative distribution function of the corresponding statistic under the alterative hypothesis (GxG
interaction present) F0(x),be the cumulative distribution function of the corresponding
statistic under the null hypothesis (GxG interaction absent) and F−0 1(x) be the inverse
function of F0(x). The corrected pOR, pRR and pChi are then defined by F 1 ðxF ðxÞÞ. Under
0

H0, F(x)=F0(x), so pOR, pRR and pChi should equal F 1 ðxF ðxÞÞ ¼ F 1 ðFx0 ðxÞÞ ¼ 1. This adjust0

0

ment will ensure the insignificant GxG interactions to have 95% confidence interactions
cross 1 under Under H0. In this work, we evaluated pOR, pRR and pChi using a full
data set while these methods can also be evaluated under the cross validation scheme
typically used in MDR.
The functions F(x) and F0(x) can be estimated by the corresponding empirical distribution function. Permutation is applied to estimate F0(x) by reshuffling the relationship
between SNPs and a phenotype, where SNPs for each individual in a system are maintained as a vector to preserve their correlation structure. For each permutation, we generated odds ratio (OR), relative risk (RR) and chi-square test statistic (Chi). Jackknife
re-sampling was applied to estimate F(x) by generating random subsets of data, where
80% to 90% of subjects were randomly selected. SNPs and the phenotype from each
subject are maintained as a vector to preserve the association between SNPs and the
phenotype. Denote the OR, RR and Chi statistic from permutation or re-sampling as
x1,x2,. . .xB where B is the number of permutation or resampling. The null distribution
XB
function F0(x) and F(x) can be estimated by B1 i¼1 Ifxi ≤xg . The 95% confidence interval pOR, pRR and pChi can be obtained by resampling. Denote the pOR, pRR and pChi
statistics from resampling or permutation as z1,z2. . .,zB then the 95% confidence interval pOR, pRR and pChi is the interval from 2.5 to 97.5 percentile of z1,z2. . .,zB from
resampling. The p-value for pOR, pRR and pChi for the ith GxG interaction, denoted
XB
by Pvaluei, will be calculated by the permutation testing, i.e. Pvaluei ¼ B1 i¼1 Ifz<zi g
where z1,z2. . .,zB are calculated from permutation samples and z is the pOR, pRR and
pChi statistic calculated from the current data.
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